Forest Labs Drug Hits a Snag

Wavecom drops on weaker demand; Qualcomm shares advance; plus more of today's stocks in the news

Forest Labs (FRX ) says the FDA will require the company to conduct additional clinical trials in order to approve the dosing regimen of lercanidipine that was requested by Forest Labs.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.